As of 2023, the prevalence of obesity in adults was 39.9%, with no significant differences between men and women, according to the Center for Disease Control and Prevention. How many people will be ...

As of 2023, the prevalence of obesity in adults was 39.9%, with no significant differences between men and women, according to the Center for Disease Control and Prevention. In data released this year ...

A Novo Nordisk designed trial reports that their 25 mg oral semaglutide taken once daily produced greater mean weight reduction than placebo over 64 weeks in adults with overweight or obesity. Rising ...

A higher weekly dose of semaglutide (7.2 mg) can significantly improve weight loss and related health outcomes in adults living with obesity, including those with type 2 diabetes (T2D), according to ...

Significantly lower risks seen for endometrial cancer, ovarian cancer, meningioma; nonsignificantly increased risk seen for kidney cancer. (HealthDay News) — For adults with obesity, glucagon-like ...

“What makes the score so powerful is its ability to predict, before the age of five, whether a child is likely to develop obesity in adulthood, well before other risk factors start to shape their ...

Nearly 19 percent of ‘overweight’ Americans would be considered under a system that considers the health effects of weight. Nearly a fifth of U.S. adults previously deemed “overweight” would be ...

Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight ...

Obesity often persists from childhood into adulthood, yet guidelines are segmented by age, lacking adolescent-specific recommendations. Discrepancies exist in BMI assessment, exercise, and dietary ...

A new study has found that older adults living with obesity can feel judged or dismissed by care providers due to their weight, leading to a reluctance to seek help. Conducted by researchers from ...

Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in ...